Rich serves as the Chairman and co-founder of several biotech companies as well as serving as a Venture Partner at ARCH Venture Partners. Rich also co-founded ORIC Pharmaceuticals serving currently as Chairman and previously as President and Chief Executive Officer. In addition, Rich serves as Chairman of Amunix Pharmaceuticals, Vividion Therapeutics, Metacrine Inc. and PMV Pharma.
Previously, Rich was the co-founder and CEO of Aragon and Seragon Pharmaceuticals, which were purchased by Johnson & Johnson and Genentech, respectively. He has been involved in the discovery and development of multiple therapeutic agents approved by the FDA, including the recently approved prostate cancer drug, Erleada® (apalutamide). Rich is the author or inventor for more than 125 publications and patents.
Rich also serves on the Board of Directors of Gritstone Oncology and Yumanity Therapeutics. In addition to his corporate experience, he is Vice Chairman of the Board of Trustees at the Salk Institute and serves on the Board Foundation for the American Association for Cancer Research, the Board of Visitors at the UCSD Moores Cancer Center and Board of Managers for Life Science Cares, San Diego.
Rich has won numerous awards, including Ernst and Young San Diego Regional Entrepreneur of the Year and the Endocrine Society Outstanding Innovation Award. He was an NIH Postdoctoral Fellow and Staff Scientist at the Salk Institute.
Rich received a Ph.D. in Pharmacology from the University of Minnesota and a B.S. in Chemistry from the University of Connecticut.
What is Richard A. Heyman's net worth?
The estimated net worth of Richard A. Heyman is at least $2.65 million as of October 18th, 2024. Dr. Heyman owns 123,673 shares of Enliven Therapeutics stock worth more than $2,646,602 as of December 4th. This net worth evaluation does not reflect any other assets that Dr. Heyman may own. Learn More about Richard A. Heyman's net worth.
How do I contact Richard A. Heyman?
Has Richard A. Heyman been buying or selling shares of Enliven Therapeutics?
Richard A. Heyman has not been actively trading shares of Enliven Therapeutics during the last ninety days. Most recently, Richard A. Heyman sold 817 shares of the business's stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a transaction totalling $24,510.00. Following the completion of the sale, the director now directly owns 123,673 shares of the company's stock, valued at $3,710,190. Learn More on Richard A. Heyman's trading history.
Who are Enliven Therapeutics' active insiders?
Are insiders buying or selling shares of Enliven Therapeutics?
In the last twelve months, insiders at the sold shares 55 times. They sold a total of 344,713 shares worth more than $7,118,196.83. The most recent insider tranaction occured on November, 19th when insider Joseph P Lyssikatos sold 12,500 shares worth more than $279,125.00. Insiders at Enliven Therapeutics own 25.9% of the company.
Learn More about insider trades at Enliven Therapeutics. Information on this page was last updated on 11/19/2025.
